5 Stocks Pushing The Health Care Sector Higher

Editor's Note: TheStreet ratings do not represent the views of TheStreet's staff or its contributors. Ratings are established by computer based on metrics for performance (which includes growth, stock performance, efficiency and valuation) and risk (volatility and solvency). Companies with poor cash flow or high debt levels tend to earn lower ratings in our model

One out of the three major indices are trading lower today with the Dow Jones Industrial Average ( ^DJI) trading down 1 points (-0.0%) at 13,971 as of Friday, Feb. 15, 2013, 11:49 AM ET. The NYSE advances/declines ratio sits at 1,429 issues advancing vs. 1,408 declining with 163 unchanged.

The Health Care sector currently is unchanged today versus the S&P 500, which is unchanged. Top gainers within the sector include Pharmacyclics Incorporated ( PCYC), up 5.1%, Biogen Idec ( BIIB), up 2.4%, Shire ( SHPG), up 2.3%, Novartis ( NVS), up 0.7% and AstraZeneca ( AZN), up 0.6%. On the negative front, top decliners within the sector include Agilent Technologies ( A), down 3.8%, Dr. Reddy Laboratories ( RDY), down 2.6%, Stryker Corporation ( SYK), down 1.0% and Thermo Fisher Scientific ( TMO), down 1.0%.

TheStreet Ratings group would like to highlight 5 stocks pushing the sector higher today:

5. Covidien ( COV) is one of the companies pushing the Health Care sector higher today. As of noon trading, Covidien is up $0.56 (0.9%) to $63.55 on average volume Thus far, 895,572 shares of Covidien exchanged hands as compared to its average daily volume of 2.2 million shares. The stock has ranged in price between $62.83-$63.60 after having opened the day at $63.14 as compared to the previous trading day's close of $62.99.

Covidien plc develops, manufactures, and sells healthcare products for use in clinical and home settings worldwide. Covidien has a market cap of $29.9 billion and is part of the health services industry. The company has a P/E ratio of 16.1, below the S&P 500 P/E ratio of 17.7. Shares are up 9.6% year to date as of the close of trading on Thursday. Currently there are 15 analysts that rate Covidien a buy, 1 analyst rates it a sell, and 2 rate it a hold.

TheStreet Ratings rates Covidien as a buy. The company's strengths can be seen in multiple areas, such as its solid stock price performance, revenue growth, attractive valuation levels, growth in earnings per share and expanding profit margins. We feel these strengths outweigh the fact that the company shows weak operating cash flow. Get the full Covidien Ratings Report now.

It's Official: Action Alerts PLUS beats the S&P 500 with Dividends Reinvested! Cramer and Link were up 16.72% in 2012. Were you? See what they are trading for 14-days FREE

4. As of noon trading, Herbalife ( HLF) is up $5.14 (13.4%) to $43.41 on heavy volume Thus far, 15.1 million shares of Herbalife exchanged hands as compared to its average daily volume of 9.6 million shares. The stock has ranged in price between $41.70-$44.93 after having opened the day at $44.15 as compared to the previous trading day's close of $38.27.

Herbalife Ltd., a network marketing company, sells weight management, nutritional supplement, energy, sports and fitness, and personal care products worldwide. Herbalife has a market cap of $3.9 billion and is part of the drugs industry. The company has a P/E ratio of 9.4, below the S&P 500 P/E ratio of 17.7. Shares are up 10.5% year to date as of the close of trading on Thursday. Currently there are 7 analysts that rate Herbalife a buy, no analysts rate it a sell, and 2 rate it a hold.

TheStreet Ratings rates Herbalife as a buy. The company's strengths can be seen in multiple areas, such as its revenue growth, notable return on equity, impressive record of earnings per share growth, increase in net income and expanding profit margins. We feel these strengths outweigh the fact that the company has had generally high debt management risk by most measures that we evaluated. Get the full Herbalife Ratings Report now.

It's Official: Action Alerts PLUS beats the S&P 500 with Dividends Reinvested! Cramer and Link were up 16.72% in 2012. Were you? See what they are trading for 14-days FREE

3. As of noon trading, Eli Lilly and Company ( LLY) is up $0.43 (0.8%) to $53.93 on light volume Thus far, 2.1 million shares of Eli Lilly and Company exchanged hands as compared to its average daily volume of 7.0 million shares. The stock has ranged in price between $53.50-$54.00 after having opened the day at $53.53 as compared to the previous trading day's close of $53.50.

Eli Lilly and Company discovers, develops, manufactures, and sells pharmaceutical products worldwide. Eli Lilly and Company has a market cap of $62.0 billion and is part of the drugs industry. The company has a P/E ratio of 15.8, below the S&P 500 P/E ratio of 17.7. Shares are up 8.4% year to date as of the close of trading on Thursday. Currently there are 5 analysts that rate Eli Lilly and Company a buy, 3 analysts rate it a sell, and 8 rate it a hold.

TheStreet Ratings rates Eli Lilly and Company as a buy. The company's strengths can be seen in multiple areas, such as its solid stock price performance and expanding profit margins. We feel these strengths outweigh the fact that the company has had sub par growth in net income. Get the full Eli Lilly and Company Ratings Report now.

It's Official: Action Alerts PLUS beats the S&P 500 with Dividends Reinvested! Cramer and Link were up 16.72% in 2012. Were you? See what they are trading for 14-days FREE

2. As of noon trading, Abbott Laboratories ( ABT) is up $0.33 (1.0%) to $35.03 on light volume Thus far, 4.5 million shares of Abbott Laboratories exchanged hands as compared to its average daily volume of 14.2 million shares. The stock has ranged in price between $34.78-$35.10 after having opened the day at $34.84 as compared to the previous trading day's close of $34.70.

Abbott Laboratories engages in the discovery, development, manufacture, and sale of health care products worldwide. Abbott Laboratories has a market cap of $54.5 billion and is part of the health services industry. The company has a P/E ratio of 6.8, below the S&P 500 P/E ratio of 17.7. Shares are up 5.2% year to date as of the close of trading on Thursday. Currently there are 8 analysts that rate Abbott Laboratories a buy, no analysts rate it a sell, and 10 rate it a hold.

TheStreet Ratings rates Abbott Laboratories as a hold. The company's strengths can be seen in multiple areas, such as its revenue growth and expanding profit margins. However, as a counter to these strengths, we also find weaknesses including unimpressive growth in net income, a generally disappointing performance in the stock itself and feeble growth in the company's earnings per share. Get the full Abbott Laboratories Ratings Report now.

It's Official: Action Alerts PLUS beats the S&P 500 with Dividends Reinvested! Cramer and Link were up 16.72% in 2012. Were you? See what they are trading for 14-days FREE

1. As of noon trading, Pfizer ( PFE) is up $0.35 (1.3%) to $27.41 on average volume Thus far, 14.3 million shares of Pfizer exchanged hands as compared to its average daily volume of 32.7 million shares. The stock has ranged in price between $27.12-$27.41 after having opened the day at $27.15 as compared to the previous trading day's close of $27.06.

Pfizer Inc., a biopharmaceutical company, engages in the discovery, development, manufacture, and sale of medicines for people and animals worldwide. Pfizer has a market cap of $198.8 billion and is part of the drugs industry. The company has a P/E ratio of 21.4, above the S&P 500 P/E ratio of 17.7. Shares are up 7.7% year to date as of the close of trading on Thursday. Currently there are 14 analysts that rate Pfizer a buy, no analysts rate it a sell, and 2 rate it a hold.

TheStreet Ratings rates Pfizer as a buy. The company's strengths can be seen in multiple areas, such as its solid stock price performance, growth in earnings per share, compelling growth in net income and expanding profit margins. Although the company may harbor some minor weaknesses, we feel they are unlikely to have a significant impact on results. Get the full Pfizer Ratings Report now.

It's Official: Action Alerts PLUS beats the S&P 500 with Dividends Reinvested! Cramer and Link were up 16.72% in 2012. Were you? See what they are trading for 14-days FREE

If you are interested in one of these 5 stocks, ETFs may be of interest. Investors who are bullish on the health care sector could consider Health Care Select Sector SPDR ( XLV) while those bearish on the health care sector could consider ProShares Ultra Short Health Care ( RXD).

A reminder about TheStreet Ratings group: TheStreet ratings do not represent the views of TheStreet's staff or its contributors. Ratings are established by computer based on metrics for performance (which includes growth, stock performance, efficiency and valuation) and risk (volatility and solvency). Companies with poor cash flow or high debt levels tend to earn lower ratings in our model.

null

More from Markets

Stocks Rise Sharply, Facebook Ignites a Nasdaq Rally

Stocks Rise Sharply, Facebook Ignites a Nasdaq Rally

Jim Cramer: Visa Is a Technology Company That Masquerades as a Financial Company

Jim Cramer: Visa Is a Technology Company That Masquerades as a Financial Company

Jim Cramer: Chipotle Shares Are Probably Done Going Down

Jim Cramer: Chipotle Shares Are Probably Done Going Down

Jim Cramer: This Is a Sad Time for Southwest Airlines

Jim Cramer: This Is a Sad Time for Southwest Airlines

Jim Cramer Just Spoke to Larry Kudlow About the China Trade Negotiations

Jim Cramer Just Spoke to Larry Kudlow About the China Trade Negotiations